ONTOCHEM GMBH has a total of 28 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2009. It filed its patents most often in WIPO (World Intellectual Property Organization), EPO (European Patent Office) and United States. Its main competitors in its focus markets pharmaceuticals, organic fine chemistry and biotechnology are PERICOR SCIENCE INC, TRIVEDI HARSH M and SPHERIUM BIOMED S L.
# | Country | Total Patents | |
---|---|---|---|
#1 | WIPO (World Intellectual Property Organization) | 6 | |
#2 | EPO (European Patent Office) | 5 | |
#3 | United States | 3 | |
#4 | Australia | 2 | |
#5 | Canada | 2 | |
#6 | China | 2 | |
#7 | Argentina | 1 | |
#8 | Brazil | 1 | |
#9 | Germany | 1 | |
#10 | Republic of Korea | 1 | |
#11 | Mexico | 1 | |
#12 | Philippines | 1 | |
#13 | Taiwan | 1 | |
#14 | South Africa | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Organic fine chemistry | |
#3 | Biotechnology | |
#4 | Measurement |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Specific use of cosmetics | |
#4 | Peptides | |
#5 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Weber Lutz | 24 |
#2 | Rennert Robert | 21 |
#3 | Richter Wolfgang | 8 |
#4 | Ahrens Verena | 6 |
#5 | Beck-Sickinger Annette G | 6 |
#6 | Lutz Weber | 4 |
#7 | Robert Rennert | 4 |
#8 | Kosel David | 3 |
#9 | Wilckens Thomas | 2 |
Publication | Filing date | Title |
---|---|---|
WO2021013999A1 | Receptor-targeting peptide-drug conjugates | |
KR20170134746A | Combinations of natural substances comprising at least one glycyrrhetinic acid and at least one excipient, and their use in cosmetic applications | |
DE102015004672A1 | In natural vesicles formulated natural product combination | |
WO2015135659A1 | Receptor ligand linked cytotoxic molecules | |
EP3074773A1 | Method for diagnosing g-protein coupled receptor-related diseases | |
EP2708243A1 | Receptor ligand linked cytotoxic molecules | |
EP2243494A1 | Pharmaceutical composition, comprising a steroid-dehydrogenase-reductase inhibitor, and a mineralocorticoid receptor antagonist. |